Skip to Main Content

Author Details

Giovanni Roti
University of Parma
2003
59
24
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37833915Uncovering NOTCH1 as a Promising Target in the Treatment of <i>MLL</i>-Rearranged Leukemia.Int J Mol Sci2023
34341479Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.Leukemia2022
35740677Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol.Cancers (Basel)2022
35710782Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia.Cell Death Dis2022
36103993ο-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro.Vascul Pharmacol2022
36017547Modern treatment approaches to adult acute T-lymphoblastic and myeloid/T-lymphoblastic leukemia: from current standards to precision medicine.Curr Opin Oncol2022
33730957Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients.Tumori2022
32366939Activating somatic and germline TERT promoter variants in myeloid malignancies.Leukemia2021
3387620914q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia.Blood2021
33611795MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia.Genes Chromosomes Cancer2021
34302727Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights.J Clin Endocrinol Metab2021
34067466Impact of the rs1024611 Polymorphism of <i>CCL2</i> on the Pathophysiology and Outcome of Primary Myelofibrosis.Cancers (Basel)2021
34151288Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.Nat Cancer2021
33407740Targeting oncogenic Notch signaling with SERCA inhibitors.J Hematol Oncol2021
32142900Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia.J Mol Diagn2020
31837925Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma.Clin Lung Cancer2020
33003595Targeting Notch Trafficking and Processing in Cancers.Cells2020
32826232The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.Cancer Discov2020
32843091New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma.Acta Neuropathol Commun2020
32361033Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC.Lung Cancer2020
32386594Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.Cell Chem Biol2020
32548224Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer.Data Brief2020
31160565Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma.Nat Commun2019
31788291Bilateral tonsillar infiltration of T-cell prolymphocytic leukemia.Clin Case Rep2019
32923866Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia.JCO Precis Oncol2019
31431717Haploidentical hematopoietic stem cell transplantation in adults using the αβTCR/CD19-based depletion of G-CSF-mobilized peripheral blood progenitor cells.Bone Marrow Transplant2019
31226848Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia.Int J Mol Sci2019
31308913Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies.Mediterr J Hematol Infect Dis2019
30923319A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes.Leukemia2019
29158376Leukemia-specific delivery of mutant NOTCH1 targeted therapy.J Exp Med2018
30537514Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling.Cancer Cell2018
29603593Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.Pediatr Blood Cancer2018
29371889Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin.Mol Cytogenet2018
29508386Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia.Int J Cancer2018
29479063High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement.Leukemia2018
29156680Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF[V600E].Oncotarget2017
28151717Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.Clin Cancer Res2017
25072021New Approaches to Target T-ALL.Front Oncol2014
23434461Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer.Cancer Cell2013
23706636Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.Chem Biol2013
22166799Genetic and proteomic approaches to identify cancer drug targets.Br J Cancer2012
22326953The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.J Clin Invest2012
22150311Targeting NOTCH1 in hematopoietic malignancy.Crit Rev Oncog2011
20161710Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.PLoS One2010
19377049Identification of AML1-ETO modulators by chemical genomics.Blood2009
17690706Different genomic imbalances in low- and high-grade HCV-related lymphomas.Leukemia2008
17143473Constitutive phosphorylation of Janus kinase 2 in the GL15 glioblastoma derived human cell line.Oncol Rep2007
17301821A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome.Leukemia2007
17296573Cryptic chromosome 9q34 deletion generates TAF-Ialpha/CAN and TAF-Ibeta/CAN fusion transcripts in acute myeloid leukemia.Haematologica2007
16643459Acute lymphoblastic leukaemia in Noonan syndrome.Br J Haematol2006
  • 1 - 50 of 59

Recommended Authors

Haijiao Zhang
Oregon Health & Science University, Knight Cancer Institute
Career Start Year 2017
Number of shared co-authors 2
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 0
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 13
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 0
Bastien Gerby
Universite de Toulouse, Inserm, Universite Toulouse III-Paul Sabatier
Career Start Year 2005
Number of shared co-authors 4
Emmanuelle Clappier
Saint-Louis Hospital
Career Start Year 2005
Number of shared co-authors 16
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 8
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 1
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 2
Christopher C Porter
Emory University School of Medicine
Career Start Year 2003
Number of shared co-authors 2
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Career Start Year 2002
Number of shared co-authors 10
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 3
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 13
Lukas D Wartman
Washington University School of Medicine in St. Louis
Career Start Year 1998
Number of shared co-authors 0
Elie Traer
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 1
Eric Tse
School of Clinical Medicine, University of Hong Kong
Career Start Year 1997
Number of shared co-authors 1
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 11
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 18
Yongjin Li
Mayo Clinic
Career Start Year 1995
Number of shared co-authors 13
Bill H Chang
Oregon Health and Science University
Career Start Year 1993
Number of shared co-authors 3
Seishi Ogawa
Kyoto University
Career Start Year 1993
Number of shared co-authors 9
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 7
Arndt Borkhardt
Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf
Career Start Year 1992
Number of shared co-authors 11
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 5
Scott A Armstrong
Boston Children's Hospital
Career Start Year 1990
Number of shared co-authors 18
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 5
Richard B Lock
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Career Start Year 1987
Number of shared co-authors 4
Alex Look
Dana-Farber Cancer Institute
Career Start Year 1975
Number of shared co-authors 21

Collaborators

Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 19
Gabriela Alexe
Dana-Farber Cancer Institute
Co-authored papers 7
Jun Qi
Dana-Farber Cancer Institute
Co-authored papers 6
Angela Su
The Broad Institute of MIT and Harvard
Co-authored papers 5
Yana Pikman
Dana Farber Cancer Institute
Co-authored papers 4
James E Bradner
Co-authored papers 3
Robin Fo??
Sapienza University.
Co-authored papers 3
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 2
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Co-authored papers 2
Rameen Beroukhim
Co-authored papers 2
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 2
Federica Piccioni
Co-authored papers 2
Christopher F Bassil
Duke University School of Medicine Durham
Co-authored papers 2
Daniel J DeAngelo
Dana-Farber Cancer Institute
Co-authored papers 2
Pratiti Bandopadhayay
Co-authored papers 2
Jia-Ren Lin
Co-authored papers 1
Gaetano Sodaro
Universite Paris Cite, INSERM, CNRS
Co-authored papers 1
Adam Tracy
Co-authored papers 1
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Co-authored papers 1
Il??ana Antony-Debr??
INSERM, France Villejuif Universite Paris-Saclay
Co-authored papers 1
Ningyan Zhang
Stem Cell Translational Research Center of Tongji Hospital, Tongji University
Co-authored papers 1
Jinghui Zhang
Changhai Hospital, Second Military Medical University
Co-authored papers 1
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Co-authored papers 1
Mary V Relling
Departments of Pharmaceutical Sciences.
Co-authored papers 1
Gael Fortin
INSERM UMR , St Louis Hospital, University of Paris
Co-authored papers 1
Ryan O'Rourke
Co-authored papers 1
Steven A Carr
Broad Institute of MIT and Harvard
Co-authored papers 1
Stefan M Pfister
Hopp Children's Cancer Center Heidelberg (KiTZ)
Co-authored papers 1
William A Weiss
University of California san francisco
Co-authored papers 1
Reinaldo Dal Bello
Universite Paris Cite, INSERM, CNRS
Co-authored papers 1
Release 1.2